PepGen Ltd

PepGen Inc. is a clinical-stage biotechnology company that develops oligonucleotide therapeutics for severe neuromuscular and neurologic diseases in the United States. Its pipeline includes PGN-EDODM1, an EDO peptide-conjugated PMO in Phase 2 clinical trials for myotonic dystrophy type 1, and FREEDOM2-DM1, also in Phase 2 for the same indication. The company is also conducting FREEDOM-OLE, an open-label expansion study. Founded in 2018, PepGen is based in Boston, Massachusetts.